Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MIR193b-365a host gene (MIR193BHG) is a long noncoding RNA (lncRNA) gene that serves as the host for two microRNAs: miR-193b and miR-365a. It is categorized as a lncRNA because it does not encode a protein but generates RNA transcripts involved in regulation. MIR193BHG is also known by the names lincNORS and HypERlnc, among others, reflecting its responsiveness to hypoxic (low oxygen) conditions and possible involvement in stress responses. Like other miRNA host genes, MIR193BHG likely affects cellular functions both by regulating the expression of hosted miRNAs and possibly through independent functions as a lncRNA. There is evidence that such genes—and their derived lncRNAs—can be involved in cancer by acting as epigenetic regulators or cancer biomarkers. However, to date, no drugs are documented to directly target MIR193BHG, and it does not represent a receptor, enzyme, or classical drug target in therapeutic development[1][2][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MIR193b-365a host gene (MIR193BHG).